Gene Therapy Market Surges to $36.55B by 2032: 5 Biotech Stocks Leading the Way

The gene therapy market is projected to reach $36.55 billion by 2032, driven by rising demand for curative treatments. Five biotech stocks, including Avant Technologies, Vertex Pharmaceuticals, CRISPR Therapeutics, Prime Medicine, and Madrigal Pharmaceuticals, are chasing the prize with their innovative approaches to address genetic diseases. The cell and gene therapy sector is expected to grow at a 17.98% compound annual rate, reaching $39.61 billion by 2034.